Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 October 2017 |
Main ID: |
NCT00001304 |
Date of registration:
|
03/11/1999 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
|
Scientific title:
|
Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34 |
Date of first enrolment:
|
October 1991 |
Target sample size:
|
27 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT00001304 |
Study type:
|
Interventional |
Study design:
|
|
Phase:
|
Phase 2
|
|
Countries of recruitment
|
United States
| | | | | | | |
Contacts
|
Name:
|
Karen K Winer, M.D. |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| | |
Key inclusion & exclusion criteria
|
- INCLUSION CRITERIA:
This study will include patients (ages 17-69) with biochemically confirmed
hypoparathyroidism.
EXCLUSION CRITERIA
Women who are pregnant will be excluded.
Age minimum:
17 Years
Age maximum:
69 Years
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Hypoparathyroidism
|
Intervention(s)
|
Drug: Synthetic Human Parathyroid Hormone 1-34
|
Drug: Calcitriol & Calcium
|
Primary Outcome(s)
|
Serum Calcium Level
[Time Frame: 3 years]
|
Urine Calcium Excretion Level
[Time Frame: 3 years]
|
Secondary Outcome(s)
|
Serum 1,25-hydroxyvitamin D Level
[Time Frame: 3 years]
|
Serum Magnesium Level
[Time Frame: 3 years]
|
Serum Phosphorus Level
[Time Frame: 3 years]
|
Urinary Creatinine Clearance
[Time Frame: 3 years]
|
Serum 25-hydroxyvitamin D Level
[Time Frame: 3 years]
|
Secondary ID(s)
|
92-CH-0011
|
920011
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
|